Physician

Harshad Vithalbhai Amin, M.D.

According to 2025 Medicare claims, Harshad Amin, M.D. (NPI: 1679807242) practices hematology/oncology in the Fort Lauderdale-Pompano Beach-Sunrise, FL market, with the plurality of this provider's patient population coming from Broward, FL. This provider's primary affiliated billing organization is SOUTH FLORIDA ONCOLOGY AND HEMATOLOGY CONSULTANTS LLC (NPI: 1700891256; TIN: 650577436) and primary practice location at 33322-5426.

Amin's data goes back to 2015 and runs through 2024. For example, in 2024, this provider had 455 traditional Medicare patients, billed 149,017 HCPCS/CPT codes, and received $3,427,718 in Medicare payments. The top billing code was 99214 (Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more). Part D data shows 3,184 prescription claims across 525 beneficiaries totaling $9,618,650 in drug costs, led by Pomalyst (Pomalidomide). 2020 DME data shows 22 claims. Open Payments data shows 364 records totaling $823,338. You can download detailed data with all billing codes (2015-2024). For more recent data, please contact us.

Over the past 10 years, this provider's Medicare Part B carrier billing has moved from a lower plateau to a higher plateau, from $470,112 to $3,427,718. Similarly, Part D prescription costs have risen steadily, from $680,895 to $9,618,650. In contrast, DME billing represents a smaller volume and did not follow a clear longitudinal pattern.

Part B Carrier Billing Trend

Medicare payment trend, with N of patients and claim lines in the table.

Year	Patients	Clm Lines	Payment
2015	441	32,938	$470,112
2016	455	79,194	$1,054,727
2017	461	79,799	$858,923
2018	422	95,901	$1,112,603
2019	475	119,114	$1,783,631
2020	397	153,259	$1,995,014
2021	400	151,464	$2,040,797
2022	423	144,726	$1,899,207
2023	465	156,684	$2,715,957
2024	455	149,017	$3,427,718

Part D Events Trend

Drug cost trend, with N of patients and prescription claims in the table.

Year	Patients	Claims	Drug Cost
2015	230	938	$680,895
2016	349	1,920	$1,698,199
2017	396	2,315	$3,068,603
2018	419	2,570	$4,371,310
2019	487	2,765	$4,342,576
2020	433	2,646	$5,420,024
2021	440	2,371	$6,241,551
2022	422	2,459	$6,887,825
2023	511	2,906	$7,009,650
2024	525	3,184	$9,618,650

DME Billing Trend

Medicare payment trend, with N of patients and DME claim records in the table.

Year	Patients	Claims	Payment
2015	N/R	36	$681
2016	N/R	85	$2,839
2017	N/R	82	$1,633
2018	N/R	34	$713
2019	N/R	N/R	N/R
2020	N/R	22	$475
2021	N/R	N/R	N/R
2022	N/R	N/R	N/R
2023	N/R	N/R	N/R
2024	N/R	N/R	N/R

* / # = suppressed by CMS; 0 = reported zero; N/R = not reported or blank.

Top 5 Part B carrier billing codes in 2024

By total payments.

Code	Description	Patients	Clm Lines	Total Payment
99214	Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more	123	163	$81
99213	Established patient office or other outpatient visit with low level od decision making, if using time, 20 minutes or more	215	376	$71
99212	Established patient office or other outpatient visit with straightforward medical decision making, if using time, 10 minutes or more	205	557	$49
96372	Injection of drug or substance under skin or into muscle	82	273	$12
85025	Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count	364	1,339	$8

Top 5 Part D drugs in 2024

By total drug costs.

Drug	Generic	Claims	Total Day Supply	Total Drug Cost
Pomalyst	Pomalidomide	59	1,652	$1,376,700
Lenalidomide	Lenalidomide	90	2,520	$1,346,594
Revlimid	Lenalidomide	34	952	$535,389
Tagrisso	Osimertinib Mesylate	31	930	$518,214
Xpovio	Selinexor	13	364	$435,513

Top 5 DME services in 2024

No connected or detailed DME service-level records for 2024.

Open Payments Summary in 2024

Category	Definition	Records	Total Reported Amount	Top Related Entity
General Payments	Reported payment or transfer-of-value amount.	275	$6,102	Bayer Healthcare Pharmaceuticals Inc.
Research Payments	Reported research-related payment or transfer-of-value amount.	89	$817,236	PFIZER INC.
Ownership / Investment Interests	Reported value of ownership or investment interests.	0	$0	N/R

Explore More Providers

FAQ

What Medicare data is available for Harshad Vithalbhai Amin, M.D.?

Tedicare shows public-source Medicare data for Harshad Vithalbhai Amin, M.D. (NPI 1679807242), including provider identity, specialty, market context, Medicare Part B activity, Part D prescribing, DME records, Open Payments where available, billing organization details, and ACO affiliation signals where available. Profile data covers 2015-2024, with current attribution based on 2025 claims where available.

Does Harshad Vithalbhai Amin, M.D. have ACO affiliation data?

No ACO affiliation record is shown in the available Tedicare data for this profile.

What billing organization is linked to Harshad Vithalbhai Amin, M.D.?

Harshad Vithalbhai Amin, M.D. is linked to SOUTH FLORIDA ONCOLOGY AND HEMATOLOGY CONSULTANTS LLC (billing NPI 1700891256) in the available physician profile data.

Does Harshad Vithalbhai Amin, M.D. have Open Payments data?

Harshad Vithalbhai Amin, M.D. has 364 connected Open Payments records in the available 2024 summary data.

Can I download physician-level Medicare data from Tedicare?

Yes. Tedicare provides sample physician export data and paid custom physician data exports for research, planning, outreach, and market analysis. Exports can include physician profile fields, market and specialty context, billing organization details, ACO affiliation signals where available, and Medicare utilization data.